000095314 001__ 95314 000095314 005__ 20210902121824.0 000095314 0247_ $$2doi$$a10.3390/cells9061525 000095314 0248_ $$2sideral$$a119056 000095314 037__ $$aART-2020-119056 000095314 041__ $$aeng 000095314 100__ $$aGascon, Marta 000095314 245__ $$aIntratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? 000095314 260__ $$c2020 000095314 5060_ $$aAccess copy available to the general public$$fUnrestricted 000095314 5203_ $$aThe molecular and cell determinants that modulate immune checkpoint (ICI) efficacy in lung cancer are still not well understood. However, there is a necessity to select those patients that will most benefit from these new treatments. Recent studies suggest the presence and/or the relative balance of specific lymphoid cells in the tumor microenvironment (TEM) including the T cell (activated, memory, and regulatory) and NK cell (CD56dim/bright) subsets, and correlate with a better response to ICI. The analyses of these cell subsets in peripheral blood, as a more accessible and homogeneous sample, might facilitate clinical decisions concerning fast prediction of ICI efficacy. Despite recent studies suggesting that lymphoid circulating cells might correlate with ICI efficacy and toxicity, more analyses and investigation are required to confirm if circulating lymphoid cells are a relevant picture of the lung TME and could be instrumental as ICI response biomarkers. This short review is aimed to discuss the recent advances in this fast-growing field. 000095314 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B29$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2017-83120-C2-1-R 000095314 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000095314 590__ $$a6.6$$b2020 000095314 591__ $$aCELL BIOLOGY$$b53 / 195 = 0.272$$c2020$$dQ2$$eT1 000095314 592__ $$a1.22$$b2020 000095314 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1 000095314 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion 000095314 700__ $$aIsla, Dolores 000095314 700__ $$aCruellas, Mara 000095314 700__ $$aGalvez, Eva M. 000095314 700__ $$aLastra, Rodrigo 000095314 700__ $$aOcariz, Maitane 000095314 700__ $$0(orcid)0000-0002-9600-8116$$aPaño, José Ramón$$uUniversidad de Zaragoza 000095314 700__ $$aRamirez, Ariel 000095314 700__ $$aSesma, Andrea 000095314 700__ $$0(orcid)0000-0003-3387-0558$$aTorres-Ramón, Irene$$uUniversidad de Zaragoza 000095314 700__ $$aYubero, Alfonso 000095314 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza 000095314 700__ $$0(orcid)0000-0003-3043-147X$$aMartinez-Lostao, Luis$$uUniversidad de Zaragoza 000095314 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000095314 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología 000095314 773__ $$g9, 6 (2020), 1525 [16 pp.]$$pCells$$tCELLS$$x2073-4409 000095314 8564_ $$s818240$$uhttps://zaguan.unizar.es/record/95314/files/texto_completo.pdf$$yVersión publicada 000095314 8564_ $$s456844$$uhttps://zaguan.unizar.es/record/95314/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000095314 909CO $$ooai:zaguan.unizar.es:95314$$particulos$$pdriver 000095314 951__ $$a2021-09-02-10:10:55 000095314 980__ $$aARTICLE